美國的生物相似藥市場:各級產品，各適應症，各流通管道，各地區，機會，預測，2018年～2032年

美國生物相似藥市場規模預計將從2024年的95.2億美元成長至2032年的291.2億美元，在2025-2032年的預測期內，複合年增長率為15%。美國生物相似藥市場的發展受到醫療保健成本上漲以及對可負擔治療方案的需求的驅動，尤其是在腫瘤和慢性病領域。可互換性認定和自動替代等監管改革正在加速生物相似藥的普及。同時，主要參與者不斷擴展產品線並採取策略性舉措，正在增強其市場影響力和患者可及性。

本報告提供美國的生物相似藥市場相關調查，提供市場概要，以及各級產品，各適應症，各流通管道，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 美國生物相似藥市場預測，2018年～2032年

• 市場規模分析與預測
• 市場佔有率分析與預測
  • 各級產品
    • 單株抗體
    • 重組的荷爾蒙
    • 免疫調節劑
    • 抗發炎劑
    • 其他
  • 各適應症
    • 腫瘤學
    • 生長激素缺乏症
    • 血液疾病
    • 慢性疾病及自體免疫疾病
    • 感染疾病
    • 其他
  • 各流通管道
    • 醫院
    • 癌症照護中心
    • 其他
  • 各地區
    • 西北部
    • 西南部
    • 西部
    • 東南部
    • 中西部
  • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
• 2024年的市場地圖分析

第6章 需求供給分析

第7章 價值鏈分析

第8章 波特的五力分析

第9章 大環境分析

第10章 價格分析

第11章 市場動態

• 市場促進因素
• 市場課題

第12章 市場趨勢與發展

第13章 法規結構和革新

• 法規當局的認證
• 臨床試驗

第14章 專利的形勢

第15章 案例研究

第16章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 前10名市場主要企業的形勢
  • Novartis AG
  • Pfizer, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Amgen, Inc.
  • Eli Lilly and Company
  • Celltrion Inc.
  • Teva Pharmaceuticals, Inc.
  • Viatris Inc.
  • Samsung Bioepis Co., Ltd.
  • Bristol-Myers Squibb Company

第17章 策略性建議

第18章 關於調查公司·免責聲明

United States biosimilars market is projected to witness a CAGR of 15% during the forecast period 2025-2032, growing from USD 9.52 billion in 2024 to USD 29.12 billion in 2032. The U.S. biosimilars market is being propelled by rising healthcare costs and demand for affordable treatment options, especially in oncology and chronic conditions. Regulatory reforms such as interchangeability designations and automatic substitution laws are accelerating biosimilar uptake. Simultaneously, expanding product pipelines and strategic initiatives by key players strengthen market presence and patient access.

Increasing Healthcare Cost Burden Driving Demand for Cost-Effective Biosimilars

The increasing expenses associated with biologic therapies in the United States have heightened the need for more cost-effective biosimilars. As the healthcare system faces challenges from the prevalence of chronic diseases, an aging population, and inflationary pressures, biosimilars present a viable alternative that maintains efficacy while being more affordable. Typically, biosimilars are introduced to the market at prices 15-35% lower than their reference biologics, which significantly alleviates treatment costs for both patients and healthcare providers. Their adoption is especially prominent in high-cost therapeutic fields such as oncology and autoimmune diseases. Additionally, the growing emphasis on value-based care by payers and the strategic placement of biosimilars in formularies are further promoting their use. Government initiatives, including the Biologics Price Competition and Innovation Act (BPCIA), continue to facilitate quicker approvals and enhance market competition. In December 2023, Pfizer reported a 43% year-over-year growth in its biosimilars portfolio in the U.S., largely driven by oncology biosimilars like ZIRABEV and NYVEPRIA. This momentum underscores how healthcare systems and providers are embracing biosimilars to enhance access, reduce drug expenditure, and improve long-term sustainability.

Expanding Oncology Indications Accelerating Market Penetration

Biosimilars are rapidly gaining popularity in oncology, a crucial sector of the U.S. pharmaceutical industry. The expiration of patents for several leading monoclonal antibodies (mAbs), including trastuzumab, rituximab, and bevacizumab, has created significant opportunities for biosimilar producers. Given that oncology treatment regimens are generally long-term and costly, they represent an ideal candidate for biosimilar replacement. The acceptance of biosimilars in clinical settings has grown as oncologists become more assured of their safety and efficacy, supported by real-world data and endorsements from the FDA. Furthermore, healthcare systems and cancer treatment centers are promoting the use of biosimilars by incorporating them into their formularies and treatment guidelines. For instance, in October 2024, Teva Pharmaceuticals and mAbxience announced an expanded collaboration agreement for the development of an anti-PD1 oncology biosimilar candidate. These advancements highlight the strategic importance of oncology in shaping biosimilar growth. The continuous pipeline of new biosimilars targeting oncologic indications is expected to further strengthen this trend, creating a ripple effect across other specialty therapeutic areas.

Supportive Regulatory Reforms and Regional Initiatives Boosting Market Expansion

The U.S. FDA has optimized the biosimilar approval process through the BPCIA, creating a more advantageous regulatory landscape for biosimilar developers. These modifications have led to shorter approval periods, enhanced interchangeability designations, and heightened trust among prescribers. On a regional level, states are enacting automatic substitution laws that permit pharmacists to replace interchangeable biosimilars without needing physician consent, thereby further promoting adoption. Additionally, the FDA's educational initiatives, including the 'Biosimilars Action Plan,' are significantly contributing to the enhancement of awareness among providers and patients. On April 14, 2025, Celltrion declared that the FDA has granted its adalimumab-aaty (marketed as YUFLYMA) an interchangeable designation. This biosimilar is based on adalimumab (known as Humira). The FDA has approved adalimumab-aaty as a high-concentration (100mg/mL) and citrate-free formulation of the reference biologic adalimumab for the treatment of various inflammatory conditions. Regional expansion is notably apparent in states with significant Medicaid participation, where biosimilars are regarded as a cost-effective alternative. With increasing regulatory backing, it is anticipated that biosimilar manufacturers will gain enhanced market access, higher adoption rates, and diminished resistance to pricing.

Future Market Scenario (2025-2032F)

The U.S. biosimilars market is set for substantial expansion in the coming decade, fueled by the expiration of patents for major biologics, rising demands to lower healthcare expenses, and supportive regulatory changes that facilitate biosimilar approvals and their interchangeability. The growing range of therapeutic uses for biosimilars in fields such as oncology, autoimmune disorders, and endocrinology will further enhance demand. As healthcare providers and payers gain greater confidence in the safety and effectiveness of biosimilars, a wider acceptance in various healthcare environments, including hospitals, cancer treatment centers, and specialized clinics-is anticipated. Moreover, increased investments from leading pharmaceutical firms and greater patient awareness will enhance market penetration. By the year 2030, the biosimilars market is expected to play a pivotal role in transforming specialty drug pricing and improving access to essential therapies for patients in the United States.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of biosimilars and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, Teva Pharmaceuticals and Alvotech have officially announced the launch of Selarsdi (ustekinumab-aekn) injection in the United States, which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). This medication is approved for treating Crohn's disease, pediatric plaque psoriasis, pediatric psoriatic arthritis, plaque psoriasis, psoriatic arthritis, and ulcerative colitis. This represents the second biosimilar introduced in the country as a result of the strategic partnership between the two companies.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. United States Biosimilars Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product Class
    • 5.2.1.1. Monoclonal Antibodies
      • 5.2.1.1.1. Adalimumab
      • 5.2.1.1.2. Infliximab
      • 5.2.1.1.3. Rituximab
      • 5.2.1.1.4. Trastuzumab
      • 5.2.1.1.5. Others
    • 5.2.1.2. Recombinant Hormones
      • 5.2.1.2.1. Insulin
      • 5.2.1.2.2. Erythropoietin
      • 5.2.1.2.3. Others
    • 5.2.1.3. Immunomodulators
    • 5.2.1.4. Anti-Inflammatory Agents
    • 5.2.1.5. Others
  • 5.2.2. By Indication
    • 5.2.2.1. Oncology
    • 5.2.2.2. Growth Hormone Deficiency
    • 5.2.2.3. Blood Disorders
    • 5.2.2.4. Chronic and Autoimmune Disorders
    • 5.2.2.5. Infectious Diseases
    • 5.2.2.6. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospitals
    • 5.2.3.2. Cancer Care Centers
    • 5.2.3.3. Others
  • 5.2.4. By Region
    • 5.2.4.1. Northwest
    • 5.2.4.2. Southwest
    • 5.2.4.3. West
    • 5.2.4.4. Southeast
    • 5.2.4.5. Midwest
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Product Class
  • 5.3.2. By Indication
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis AG
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Pfizer, Inc.
  • 16.3.3. Dr. Reddy's Laboratories Ltd.
  • 16.3.4. Amgen, Inc.
  • 16.3.5. Eli Lilly and Company
  • 16.3.6. Celltrion Inc.
  • 16.3.7. Teva Pharmaceuticals, Inc.
  • 16.3.8. Viatris Inc.
  • 16.3.9. Samsung Bioepis Co., Ltd.
  • 16.3.10. Bristol-Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Biosimilars Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Biosimilars Market Share (%), By Product Class, 2018-2032F
• Figure 3. United States Biosimilars Market Share (%), By Indication, 2018-2032F
• Figure 4. United States Biosimilars Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. United States Biosimilars Market Share (%), By Region, 2018-2032F
• Figure 6. By Product Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 7. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024